Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Summary

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2015-09-28

Primary completion

2027-01-01

Completion

2028-01

Publications

• Brastianos PK, Dooley K, Geyer S, Gerstner ER, Kaufmann TJ, Iafrate AJ, Martinez-Lage M, Milhem M, Welch MR, Kaley TJ, Drappatz J, Chan A, Kumthekar P, Matsuoka CK, Strowd RE, Cohen AL, Jaeckle K, Robell L, Magge RS, Nam JY, Blondin N, Shaikh N, Rabinowitz I, Thomas AA, Piccioni DE, Brown P, Kaluziak S, Codd E, Cahill DP, Santagata S, Barker FG 2nd, Galanis E. Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. Nat Med. 2026 Feb;32(2):717-724. doi: 10.1038/s41591-025-04141-4. Epub 2026 Jan 16.
• Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol. 2023 Jan 20;41(3):618-628. doi: 10.1200/JCO.21.02371. Epub 2022 Oct 26.

Drugs

Indications